Hansa starts dosing in Phase III trial in anti-GBM disease
Sweden-based Hansa Biopharma doses first anti-GMB patient with imlifidase in a Phase…
Search
Have an existing account?
Sign In
Urtė Fultinavičiūtė
1
Follow US
Find US on Social Medias
Popular News
Global Coronavirus Cases
Confirmed
0
Death
0
